Login to Your Account



Philogen bid targets earlier melanoma, phase III injecting lesions

By Randy Osborne
Staff Writer

Thursday, January 21, 2016

Philogen SpA's "idea is to stop [melanoma] when you have metastases, but only at the skin," co-founder Dario Neri told BioWorld Today, as his firm launched its pivotal trial in about 200 patients testing Darleukin against stage IIIb/c disease, which "almost invariably" worsens to often-fatal stage IV within two years.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription